342 related articles for article (PubMed ID: 1466849)
1. Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity.
Slavin MA; Hoy JF; Stewart K; Pettinger MB; Lucas CR; Kent SJ
AIDS; 1992 Oct; 6(10):1169-74. PubMed ID: 1466849
[TBL] [Abstract][Full Text] [Related]
2. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine.
Mallolas J; Zamora L; Gatell JM; Miró JM; Vernet E; Valls ME; Soriano E; SanMiguel JG
AIDS; 1993 Jan; 7(1):59-64. PubMed ID: 8442918
[TBL] [Abstract][Full Text] [Related]
3. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia.
Warnock AC; Rimland D
Pharmacotherapy; 1996; 16(6):1030-8. PubMed ID: 8947975
[TBL] [Abstract][Full Text] [Related]
4. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group.
Girard PM; Landman R; Gaudebout C; Olivares R; Saimot AG; Jelazko P; Gaudebout C; Certain A; Boué F; Bouvet E
N Engl J Med; 1993 May; 328(21):1514-20. PubMed ID: 8479488
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients.
Martin MA; Cox PH; Beck K; Styer CM; Beall GN
Arch Intern Med; 1992 Mar; 152(3):523-8. PubMed ID: 1546914
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
Torres RA; Barr M; Thorn M; Gregory G; Kiely S; Chanin E; Carlo C; Martin M; Thornton J
Am J Med; 1993 Dec; 95(6):573-83. PubMed ID: 8018144
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.
Bozzette SA; Finkelstein DM; Spector SA; Frame P; Powderly WG; He W; Phillips L; Craven D; van der Horst C; Feinberg J
N Engl J Med; 1995 Mar; 332(11):693-9. PubMed ID: 7854375
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Pneumocystis carinii pneumonia in patients with AIDS.
Wordell CJ; Hauptman SP
Clin Pharm; 1988 Jul; 7(7):514-27. PubMed ID: 3138063
[TBL] [Abstract][Full Text] [Related]
9. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens.
Ioannidis JP; Cappelleri JC; Skolnik PR; Lau J; Sacks HS
Arch Intern Med; 1996 Jan; 156(2):177-88. PubMed ID: 8546551
[TBL] [Abstract][Full Text] [Related]
10. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial.
Leoung GS; Feigal DW; Montgomery AB; Corkery K; Wardlaw L; Adams M; Busch D; Gordon S; Jacobson MA; Volberding PA
N Engl J Med; 1990 Sep; 323(12):769-75. PubMed ID: 1975426
[TBL] [Abstract][Full Text] [Related]
11. A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia.
Hirschel B; Lazzarin A; Chopard P; Opravil M; Furrer HJ; Rüttimann S; Vernazza P; Chave JP; Ancarani F; Gabriel V
N Engl J Med; 1991 Apr; 324(16):1079-83. PubMed ID: 2008181
[TBL] [Abstract][Full Text] [Related]
12. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.
Saah AJ; Hoover DR; Peng Y; Phair JP; Visscher B; Kingsley LA; Schrager LK
JAMA; 1995 Apr; 273(15):1197-202. PubMed ID: 7707627
[TBL] [Abstract][Full Text] [Related]
13. [Randomized comparative study of secondary prevention of Pneumocystis carinii pneumonia in patients with acquired immunologic deficiency syndrome].
Höffken G; Elsing C; Ruhnke M; Franke M; Schrappe-Bächer M; Stellbrink HJ; Weiss R; Noack H; Petri M; Lode H
Med Klin (Munich); 1990 Apr; 85 Suppl 2():281-5. PubMed ID: 2197538
[TBL] [Abstract][Full Text] [Related]
14. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
Antinori A; Murri R; Ammassari A; De Luca A; Linzalone A; Cingolani A; Damiano F; Maiuro G; Vecchiet J; Scoppettuolo G
AIDS; 1995 Dec; 9(12):1343-50. PubMed ID: 8605054
[TBL] [Abstract][Full Text] [Related]
15. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients.
Opravil M; Hirschel B; Lazzarin A; Heald A; Pechère M; Rüttimann S; Iten A; von Overbeck J; Oertle D; Praz G
Clin Infect Dis; 1995 Mar; 20(3):531-41. PubMed ID: 7756472
[TBL] [Abstract][Full Text] [Related]
16. Pneumocystis carinii pneumonia prophylaxis during pregnancy.
Connelly RT; Lourwood DL
Pharmacotherapy; 1994; 14(4):424-9. PubMed ID: 7937279
[TBL] [Abstract][Full Text] [Related]
17. Optimizing PCP therapy.
Torres G; Cadman J
GMHC Treat Issues; 1997 Oct; 11(10):3-5. PubMed ID: 11364821
[TBL] [Abstract][Full Text] [Related]
18. [Prospective study of primary and secondary prevention of Pneumocystis carinii pneumonia with pentamidine aerosol].
Staszewski S; Trinder S; Gottstein A; Odewald J; Rehmet S; Brodt R; Jacobi V; Müller R; Müller H; Helm EB
Med Klin (Munich); 1990 Apr; 85 Suppl 2():271-5. PubMed ID: 2374530
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection.
Schürmann D; Bergmann F; Albrecht H; Padberg J; Wünsche T; Grünewald T; Schürmann M; Grobusch M; Vallée M; Ruf B; Suttorp N
Eur J Clin Microbiol Infect Dis; 2002 May; 21(5):353-61. PubMed ID: 12072919
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
